With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn phenomenon, and improved overnight sleep
Tackling hyperglycemia to improve long-term health with type 1 diabetes
Among the burdens of living with diabetes, hyperglycemia can often be overshadowed by hypoglycemia. Yet, in the
One cause of high blood sugars is the dawn phenomenon, an increase in glucose levels in the early morning.4 This can be a common occurrence for those living with diabetes and may add to feelings of frustration with diabetes. An encouraging new retrospective analysis of real-world data (n= 6026) showed that this morning peak was nearly eliminated for users who upgraded from the MiniMed™ 770G system to the MiniMed™ 780G system. The data assessed the elevation of sensor glucose levels >20 mg/dL from
Early and consistent management of hyperglycemia is critical as it has protective effects on the body that can last for decades.5 "For those living with type 1 diabetes, dawn phenomenon can be a stressful occurrence that feels out of one's control," explained Robert Vigersky, MD, Chief Medical Officer,
Reducing nighttime burden
For individuals living with type 1 diabetes, CGM-generated alerts and the need to deliver manual boluses disrupt sleeping through the night adding to the burden of diabetes. The MiniMed™ 780G system is designed to reduce the burden of diabetes throughout the day and night. Additional real-world data from a retrospective analysis presented at
The continued evolution of the MiniMed™ 780G system to reduce burden
Along with evidence on the currently available MiniMed™ 780G system, additional data will be presented on the next iteration of the system,* which aims to further reduce diabetes management burden through its design. The system is intended to be paired with the Simplera Sync™ sensor, a disposable, all-in-one continuous glucose monitor (CGM) designed to require no overtape.
A 24-site, single arm study evaluated the use of the next iteration of the MiniMed™ 780G system algorithm paired with the Simplera Sync™ sensor. Results were promising across all clinical outcomes metrics including Time in Range (TIR), Time in
"The MiniMed™ 780G system has firmly established itself as a proven automated insulin delivery system," said study investigator
The MiniMed™ 780G system** is currently available for ages 7 and above in over 100 countries globally and will be launching with the Simplera Sync™ sensor in parts of
Safety and Glycemic Outcomes Using the MiniMed™ 780G system with an | ||||||||
Youths (ages 7-17) | Adults (ages 18-80) | |||||||
Run-in | Study | ROS | Run-in | Study | ROS | |||
Time in Smart Guard, | 14.5±31.3 | 93.5±11.3 | 96.9±3.1 | 33.2±40.3 | 96.6±6.6 | 97.5±3.7 | ||
Mean SG, mg/dL | 180.4±27.1 | 154.4±17.6 | 149.0±15.3 | 161.0±18.7 | 142.2±12.8 | 136.5±12.0 | ||
Percentage of time spent at glucose ranges | ||||||||
<70 mg/dL (% TBR) | 1.6±1.7 | 1.9±1.4 | 1.9±1.2 | 1.7±1.9 | 1.5±1.4 | 1.7±1.4 | ||
70-140 mg/dL (% TITR) | 32.1±14.1 | 49.2±9.7 | 52.7±9.2 | 39.2±13.0 | 56.1±10.5 | 61.6±9.9 | ||
70-180 mg/dL (% TIR) | 54.4±15.7 | 71.4±9.9 | 74.7±9.3 | 66.5±12.6 | 80.2±8.1 | 83.8±7.4 | ||
>180 mg/dL (% TAR) | 44.0±16.1 | 26.7±10.1 | 23.3±9.4 | 31.8±13.1 | 18.2±8.4 | 14.5±7.7 | ||
Caption: Glycemic metrics and insulin delivered during youth and adult MiniMed™ 780G system investigational use with the disposable all-in-one Simplera Sync™ sensor
To view this data at the 84th American Diabetes Association (ADA) Scientific Sessions in Orlando,
About Medtronic
Bold thinking. Bolder actions. We are Medtronic.
About
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the
*Investigational. Not approved by the FDA for any use and not commercially available in the US.
**MiniMed™ 780G system is for type 1 ages 7 and over. Prescription required. WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day. For details, see https://bit.ly/780gRisks
† Refers to auto correct, which provides bolus assistance. Can deliver all auto correction doses automatically without user interaction, feature can be turned on and off.
§ Refers to SmartGuard™ feature. Individual results may vary.
- Ebekozien O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. 2023 Nov;25(11):765-773. doi: 10.1089/dia.2023.0320. Epub 2023 Oct 16. PMID: 37768677.
The Diabetes Control and Complications Trial Research Group . The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. N Engl J Med 1993; 329:977-986- Mauras N, Buckingham B, White NH, Tsalikian E,
Weinzimer SA , Jo B, Cato A, Fox LA, Aye T, Arbelaez AM, Hershey T, Tansey M, Tamborlane W, Foland-Ross LC, Shen H, Englert K, Mazaika P, Marzelli M, Reiss AL;Diabetes Research in Children Network (DirecNet). Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study. Diabetes Care. 2021 Apr;44(4):983-992. - O'Neal, Teri B. "Dawn Phenomenon."
U.S. National Library of Medicine ,16 May 2023 , www.ncbi.nlm.nih.gov/books/NBK430893/. - Lachin JM, Bebu I, Nathan DM;
DCCT/EDIC Research Group . The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes. Diabetes Care. 2021 Aug 11;44(10):2225–30. - Arrieta A, Battelino T, Scaramuzza AE, Da Silva J, Castañeda J, Cordero TL, Shin J, Cohen O. Comparison of MiniMed™ 780G system performance in users aged younger and older than 15 years: Evidence from 12 870 real-world users. Diabetes Obes Metab. 2022 Jul;24(7):1370-1379.
- Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, Close KL. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019 Mar;42(3):400-405. doi: 10.2337/dc18-1444. Epub 2018 Oct 23. PMID: 30352896; PMCID: PMC6905478.
Contacts: | |
Ryan Weispfenning | |
Public Relations | Investor Relations |
+1 (818) 576-3025 | +1 (763) 505-4626 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-minimed-780g-system-data-demonstrates-ability-to-address-persistent-blood-sugar-challenges-for-people-with-type-1-diabetes-302179448.html
SOURCE
© Canada Newswire, source